Viracta Therapeutics Inc. (NASDAQ:VIRX) went down by -9.74% from its latest closing price compared to the recent 1-year high of $12.93. The company’s stock price has collected 0.42% of gains in the last five trading sessions.
Is It Worth Investing in Viracta Therapeutics Inc. (NASDAQ :VIRX) Right Now?
Plus, the 36-month beta value for VIRX is at 2.22. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Viracta Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $20.00, which is $18.99 above the current price. VIRX currently public float of 22.74M and currently shorts hold a 8.78% ratio of that float. Today, the average trading volume of VIRX was 243.20K shares.
VIRX’s Market Performance
VIRX stocks went up by 0.42% for the week, with a monthly jump of 14.22% and a quarterly performance of -30.75%, while its annual performance rate touched -79.59%. The volatility ratio for the week stands at 10.39% while the volatility levels for the past 30 days are set at 12.71% for Viracta Therapeutics Inc. The simple moving average for the period of the last 20 days is 0.27% for VIRX stocks with a simple moving average of -42.71% for the last 200 days.
Analysts’ Opinion of VIRX
Many brokerage firms have already submitted their reports for VIRX stocks, with RBC Capital Mkts repeating the rating for VIRX by listing it as a “Outperform.” The predicted price for VIRX in the upcoming period, according to RBC Capital Mkts is $10 based on the research report published on February 01st of the current year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VIRX reach a price target of $35. The rating they have provided for VIRX stocks is “Buy” according to the report published on May 03rd, 2021.
SVB Leerink gave a rating of “Outperform” to VIRX, setting the target price at $18 in the report published on April 26th of the previous year.
VIRX Trading at -7.25% from the 50-Day Moving Average
After a stumble in the market that brought VIRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.36% of loss for the given period.
Volatility was left at 12.71%, however, over the last 30 days, the volatility rate increased by 10.39%, as shares surge +14.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.21% lower at present.
During the last 5 trading sessions, VIRX rose by +0.42%, which changed the moving average for the period of 200-days by -73.25% in comparison to the 20-day moving average, which settled at $2.42. In addition, Viracta Therapeutics Inc. saw -33.97% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at VIRX starting from Rojkjaer Lisa, who sale 2,154 shares at the price of $1.90 back on May 26. After this action, Rojkjaer Lisa now owns 42,168 shares of Viracta Therapeutics Inc., valued at $4,095 using the latest closing price.
ROYSTON IVOR, the CEO & President of Viracta Therapeutics Inc., sale 13,162 shares at $1.90 during a trade that took place back on May 26, which means that ROYSTON IVOR is holding 600,930 shares at $25,022 based on the most recent closing price.
Stock Fundamentals for VIRX
Current profitability levels for the company are sitting at:
- -1123.40 for the present operating margin
The net margin for Viracta Therapeutics Inc. stands at -1125.42. The total capital return value is set at -103.01, while invested capital returns managed to touch -146.69. Equity return is now at value -48.60, with -40.80 for asset returns.
Based on Viracta Therapeutics Inc. (VIRX), the company’s capital structure generated 22.81 points at debt to equity in total, while total debt to capital is 18.57. Total debt to assets is 16.87, with long-term debt to equity ratio resting at 1.72. Finally, the long-term debt to capital ratio is 0.80.
When we switch over and look at the enterprise to sales, we see a ratio of 6.20, with the company’s debt to enterprise value settled at 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.86.